A phase I/II dose finding study evaluating the safety and tolerability of CAPecitabine and AflIbercept in patients with unresectable metasTAtic colorectaL cancer deemed unsuitable for doublet/ triplet chemotherapy.
Latest Information Update: 12 Feb 2018
At a glance
- Drugs Aflibercept (Primary) ; Capecitabine
- Indications Colorectal cancer
- Focus Adverse reactions
- Acronyms CAPITAL
- 31 Aug 2018 Biomarkers information updated
- 27 Feb 2016 Status changed from recruiting to completed as per ISRCTN: Current Controlled Trials record.
- 26 Nov 2015 Accrual to date is 37% according to United Kingdom Clinical Research Network record.